RxDoctor Payments Data

Linda Zhang, MD

Glaucoma Specialist · Warren, NJNPI 1831358381

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $511 of the $610 with a category attached, or 83.7%. 10 manufacturers reported payments, led by Stryker at 27.3% of the total.

$610in general payments, 2019–2025

Across 14 payments — averaging $43.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$167
  • Nevro Corp.$144
  • AbbVie$96
  • Rxsight Inc$70
  • Oyster Point Pharma, Inc.$39
  • Alcon$20
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$51184%
  • Education$8013%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$307,642
Medicare patients
587
Services billed
2,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost90$46,308
VyzultaLatanoprostene Bunod73$33,172
RestasisCyclosporine16$24,241
Timolol Maleate198$18,900
Cyclosporine28$13,417
Brimonidine Tartrate149$10,758
SimbrinzaBrinzolamide/Brimonidine Tart19$10,115
Prednisolone Acetate232$9,152
Travoprost62$8,233
ProlensaBromfenac Sodium21$7,487
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol34$7,152
RhopressaNetarsudil Mesylate12$6,533
Latanoprost467$5,608
Travatan ZTravoprost14$5,007
TafluprostTafluprost/Pf18$4,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$96$70,549106 claims
AlconSimbrinza$20$10,11519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Warren

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →